AL-S Pharma AG
PrivateLast Round
VC Round
Dec 7, 2016
Company Overview
AL-S Pharma AG is a clinical-stage biotechnology company developing AP-101, an antibody therapeutic for the treatment of amyotrophic lateral sclerosis (ALS).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AL-S Pharma AG Comparables
Compare AL-S Pharma AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axoltis Pharma | 78% | |
| Prilenia Therapeutics | 78% | |
| QurAlis | 77% | |
AL-S Pharma AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 7, 2016 |
AL-S Pharma AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TVM Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 7, 2016
Raised capital from TVM Capital and Neurimmune AG.
AL-S Pharma AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AL-S Pharma AG's valuation, stock price, and market status.